Background-Silent information regulator 1 (Sirt1), a class III histone deacetylase, retards aging and protects the heart from oxidative stress. We here examined whether Sirt1 is protective against myocardial ischemia/reperfusion (I/R). Methods and Results-Protein and mRNA expression of Sirt1 is significantly reduced by I/R. Cardiac-specific Sirt1 Ϫ/Ϫ mice exhibited a significant increase (44Ϯ5% versus 15Ϯ5%; Pϭ0.01) in the size of myocardial infarction/area at risk. In transgenic mice with cardiac-specific overexpression of Sirt1, both myocardial infarction/area at risk (15Ϯ4% versus 36Ϯ8%; Pϭ0.004) and terminal deoxynucleotidyl transferase dUTP nick end labeling-positive nuclei (4Ϯ3% versus 10Ϯ1%; PϽ0.003) were significantly reduced compared with nontransgenic mice. In Langendorff-perfused hearts, the functional recovery during reperfusion was significantly greater in transgenic mice with cardiac-specific overexpression of Sirt1 than in nontransgenic mice. Sirt1 positively regulates expression of prosurvival molecules, including manganese superoxide dismutase, thioredoxin-1, and Bcl-xL, whereas it negatively regulates the proapoptotic molecules Bax and cleaved caspase-3. The level of oxidative stress after I/R, as evaluated by anti-8-hydroxydeoxyguanosine staining, was negatively regulated by Sirt1. Sirt1 stimulates the transcriptional activity of FoxO1, which in turn plays an essential role in mediating Sirt1-induced upregulation of manganese superoxide dismutase and suppression of oxidative stress in cardiac myocytes. Sirt1 plays an important role in mediating I/R-induced increases in the nuclear localization of FoxO1 in vivo. Conclusions-These results suggest that Sirt1 protects the heart from I/R injury through upregulation of antioxidants and downregulation of proapoptotic molecules through activation of FoxO and decreases in oxidative stress. (Circulation. 2010;122:2170-2182.)
To address these issues, we used genetically altered mouse models in which expression of Sirt1 is either upregulated or downregulated in a cardiac myocyte-specific manner. In particular, we asked (1) how expression of Sirt1 is affected by I/R, (2) how upregulation or downregulation of Sirt1 in cardiac myocytes affects myocardial injury and cardiac function after I/R, and (3) whether stimulation of Sirt1 activates cell-protective mechanisms in the heart during I/R.
Methods

Genetically Altered Mouse Models
Cardiac-specific Sirt1 transgenic mice (Tg-Sirt1) were generated with the use of the ␣-myosin heavy chain promoter (courtesy of Dr J. Robbins, Children's Hospital, Cincinnati, Ohio) on an FVB background. The baseline cardiac phenotype of Tg-Sirt1 mice (line 40) has been described. 22 Cardiac-specific Sirt1 knockout (Sirt1 Ϫ/Ϫ ) mice were generated by crossing Sirt1 flox/flox mice (Jackson Laboratory) with C57BL/6J background with ␣-myosin heavy chain promoter-driven Cre mice (␣MHC-Cre, courtesy of Dr M. Schneider, Imperial College, London, UK). All Sirt1 flox/flox (control) and Sirt1 flox/flox,␣MHC-Cre (cardiac-specific Sirt1 Ϫ/Ϫ ) mice were backcrossed to C57BL/6J background. All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey.
Antibodies
The antibodies used in this study include anti-Sirt1 and antimanganese superoxide dismutase (MnSOD) antibodies (Millipore, Billerica, Mass), anti-acetylated-p53 (Lys-382) antibody (Abcam, Cambridge, Mass), anti-Bcl-xL antibody (BD Biosciences, San Jose, Calif), anti-Bax, anti-8-hydroxydeoxyguanosine , and anti-FoxO1 antibodies (Santa Cruz Biotechnology Inc, Santa Cruz, Calif), anti-cleaved caspase-3 and anti-acetylated FoxO1 antibodies (Cell Signaling Technology, Danvers, Mass), anti-troponin T antibody (Thermo Scientific, Waltham, Mass), and anti-actinin and anti-tubulin antibodies (Sigma, St Louis, Mo). The anti-thioredoxin1 (Trx1) antibody has been described previously. 24 
I/R and Prolonged Ischemia In Vivo
Mice were housed in a temperature-controlled environment with 12-hour light/dark cycles where they received food and water ad libitum. Mice were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg). A rodent ventilator (model 683; Harvard Apparatus Inc) was used with 65% oxygen. The animals were kept warm with heat lamps. Rectal temperature was monitored and maintained between 36°C and 37°C. The chest was opened by a horizontal incision at the third intercostal space. I/R was achieved by ligating the anterior descending branch of the left coronary artery with an 8-0 Prolene suture, with silicon tubing (1 mm outer diameter) placed on top of the left anterior descending coronary artery, 2 mm below the border between the left atrium and left ventricle (LV). Ischemia was confirmed by ECG change (ST elevation). After occlusion for 45 minutes in mice of FVB background and 20 to 30 minutes in mice of C57BL/6J background, the silicon tubing was removed to achieve reperfusion, and the rib space and overlying muscles were closed. FVB mice were subjected to longer ischemia because they are more resistant to I/R injury. Some mice were subjected to alternating brief periods of ischemia (1.5 minutes, 4 times) and reperfusion (3.5 minutes, 4 times) before a longer period (20 minutes) of ischemia. When recovered from anesthesia, the mice were extubated and returned to their cages. They were housed in a climate-controlled environment. Twenty-four hours after reperfusion, the animals were reanesthetized and intubated, and the chest was opened. After the heart was arrested at the diastolic phase by KCl injection, the ascending aorta was canulated and perfused with saline to wash out blood. The left anterior descending coronary artery was occluded with the same suture, which had been left at the site of the ligation. To demarcate the ischemic area at risk (AAR), Alcian blue dye (1%) was perfused into the aorta and coronary arteries. Hearts were excised, and LVs were sliced into 1-mm-thick cross sections. The heart sections were then incubated with a 1% triphenyltetrazolium chloride solution at 37°C for 15 minutes. The infarct area (pale), the AAR (not blue), and the total LV area from both sides of each section were measured with the use of Adobe Photoshop (Adobe Systems Inc), and the values obtained were averaged. The percentages of area of infarction and AAR of each section were multiplied by the weight of the section and then totaled from all sections. AAR/LV and infarct area/AAR were expressed as percentages. 25
Langendorff-Perfused Mouse Heart Model of Global I/R
Mice were anesthetized with pentobarbital (65 mg/kg IP) and treated intraperitoneally with 50 U of heparin. The heart was quickly removed and catheterized with a 22-gauge needle. The hearts were mounted on a Langendorff-type isolated heart perfusion system and subjected to retrograde coronary artery reperfusion with 37°C oxygenated Krebs-Henseleit bicarbonate buffer (mmol/L: NaCl 120, glucose 17, NaHCO 3 25, KCl 5.9, MgCl 2 1.2, CaCl 2 2.5, EDTA 0.5), pH 7.4, at a constant pressure of 80 mm Hg. A balloon filled with water was introduced into the LV through the mitral valve orifice and connected to a pressure transducer via a plastic tube primed with water. LV pressures and LV dP/dt were recorded with a strip chart recorder (Astro-Med Inc). The LV end-diastolic pressure was set at 4 to 10 mm Hg at the beginning of perfusion by adjusting the volume of the balloon in the LV, and the volume was kept constant throughout an experiment. After a 30-minute equilibration period, the heart was subjected to 30 minutes of global ischemia (at 37°C) followed by 60 minutes of reperfusion.
Evaluation of Apoptosis in Tissue Sections
DNA fragmentation was detected in situ with the use of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), as described. 25 Nuclear density was determined by manual counting of DAPI-stained nuclei in 6 fields for each animal with the ϫ40 objective, and the number of TUNEL-positive nuclei was counted by examining the entire section with the same power objective.
Immunoblot Analysis
For immunoblot analysis, heart samples were homogenized in lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 0.1% sodium dodecyl sulfate, 1% Igepal CA-630, 0.15 mol/L NaCl, 0.25% Na-deoxycholate, and 1 mmol/L EDTA supplemented with protease inhibitors).
Adenovirus Constructs
Adenovirus harboring Sirt1 has been described. 21 Adenovirus harboring small hairpin RNA for FoxO1 (Ad-sh-FoxO1) was generated as described previously 26 with the use of the following hairpin forming oligo 5Ј-CGCCAAACTCACTACACCATTTCAAGAGA-ATGGTGTAGTGAGTTTGGCTTTTTA-3Ј. The hairpin loop sequence is italicized.
Statistical Analysis
Data are expressed as meanϮSEM, but nonparametric statistics were employed because of the small numbers of subjects. Differences in means between 2 groups and among Ͼ2 groups were evaluated with Mann-Whitney U test and Kruskal-Wallis test, respectively. The post hoc comparisons were performed by Mann-Whitney U test with Bonferroni correction when the multigroup comparisons were significant. Hemodynamic data between 2 groups at different times of reperfusion were compared with linear mixed models. All of the statistical analyses were performed with the use of SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). P values of Ͻ0.05 were considered statistically significant.
Results
Sirt1 Is Downregulated by I/R
C57BL/6J mice were subjected to 20 minutes of ischemia followed by 24 hours of reperfusion (I/R) ( Figure 1A ). Expression of Sirt1 was significantly reduced in hearts subjected to I/R compared with sham-operated hearts (66.6Ϯ1.8%; Pϭ0.009 versus sham-operated hearts) ( Figure  1B ). Downregulation of Sirt1 was normalized (113.9Ϯ12.0%) in hearts subjected to preconditioning before I/R (4 cycles of 1.5 minutes of ischemia followed by 3.5 minutes of reperfusion) ( Figure 1A and 1B). Similar results were obtained in regard to the effect of I/R and preconditioning on mRNA expression of Sirt1 ( Figure 1B ).
Downregulation of Endogenous Sirt1 in the Heart Exacerbates Myocardial Injury Caused by I/R
To examine the role of endogenous Sirt1 in mediating survival and death of cardiac myocytes, we used cardiacspecific Sirt1 Ϫ/Ϫ mice. Expression of Sirt1 was selectively attenuated in the heart, and there was no compensatory increase in Sirt3 expression in cardiac-specific Sirt1 Ϫ/Ϫ mice ( Figure I in the online-only Data Supplement). The cardiac phenotype in cardiac-specific Sirt1 Ϫ/Ϫ mice was normal at 3 months of age ( Table I in the online-only Data Supplement). Cardiac-specific Sirt1 Ϫ/Ϫ mice or control wild-type mice were subjected to 30 minutes of ischemia followed by 24 hours of reperfusion. The AAR/LV in cardiac-specific Sirt1 Ϫ/Ϫ mice was not significantly different from that in control mice. The size of myocardial infarction/AAR was significantly greater in cardiac-specific Sirt1 Ϫ/Ϫ than in control mice (Figure 2A and 2B), suggesting that endogenous Sirt1 plays a protective role in the heart during I/R.
Overexpression of Sirt1 in the Heart Is Protective Against I/R Injury
Because downregulation of endogenous Sirt1 in the heart subjected to I/R appears to promote myocardial injury, we hypothesized that upregulation of Sirt1 in the heart prevents myocardial injury in response to I/R. To evaluate the effect of increased expression of Sirt1 on myocardial injury caused by I/R, Tg-Sirt1 and nontransgenic mice generated on an FVB background were subjected to 45 minutes of ischemia followed by 24 hours of reperfusion ( Figure 3A ). We confirmed that Sirt1 is significantly upregulated in the myocardium of Tg-Sirt1 compared with nontransgenic mice ( Figure IIA and IIB in the online-only Data Supplement). The level of acetylated p53 was significantly reduced in Tg-Sirt1, indicating that the activity of Sirt1 is elevated in Tg-Sirt1 (not shown). The size of AAR/LV was not significantly different between Tg-Sirt1 and nontransgenic mice ( Figure 3B ), but the size of myocardial infarction/AAR after I/R was significantly smaller in Tg-Sirt1 than in nontransgenic mice ( Figure  3B ). The number of TUNEL-positive cells in the ischemic border zone was also smaller in Tg-Sirt1 mice than in nontransgenic mice ( Figure 3C ).
The effect of Sirt1 on I/R injury was also evaluated in the Langendorff-perfused isolated heart model. Hearts isolated from Tg-Sirt1 or nontransgenic mice were subjected to 30 minutes of global ischemia followed by 60 minutes of reperfusion ( Figure 4A ). The baseline LV function of Tg-Sirt1 and nontransgenic mouse hearts was similar ( Table II in the online-only Data Supplement). After reperfusion, recovery of LV systolic pressure and LV developed pressure was significantly greater in Tg-Sirt1 than in nontransgenic mice ( Figure 4B and 4C ). LV end-diastolic pressure did not differ significantly between Tg-Sirt1 and nontransgenic mice (Figure 4D ). However, both systolic and diastolic dP/dt were significantly improved ( Figure 4E and 4F). The size of myocardial infarction evaluated by triphenyltetrazolium chloride staining was significantly smaller in Tg-Sirt1 mice than in nontransgenic mice ( Figure 4G ). Taken together, these results suggest that Sirt1 plays a protective role against myocardial dysfunction and injury caused by I/R.
Sirt1 Upregulates Antioxidant and Antiapoptotic Molecules and Downregulates Proapoptotic Molecules in the Heart
We investigated the molecular mechanism by which Sirt1 protects the heart from I/R injury. Homogenates were prepared from the ischemic area in Tg-Sirt1 and nontransgenic hearts subjected to I/R, and expression of molecules involved in survival and death of cardiac myocytes was evaluated. Expression of MnSOD (6.6Ϯ1.8-fold versus nontransgenic) and Trx1 (2.4Ϯ0.3-fold) antioxidants was significantly higher in Tg-Sirt1 than in nontransgenic mice ( Figure 5A through 5C ). Expression of Bcl-xL (2.0Ϯ0.3fold), an antiapoptotic molecule, was also increased (Figure 5A and 5D ). On the other hand, expression of Bax (0.2Ϯ0.03-fold) and cleaved caspase-3 (0.4Ϯ0.14-fold), proapoptotic molecules, was significantly lower in Tg-Sirt1 than in nontransgenic mice (Figure 5A , 5E, and 5F). To examine whether changes in the levels of the aforementioned molecules in Tg-Sirt1 occur in cardiac myocytes, immunostaining was conducted. We confirmed that both upregulation of Bcl-xL and downregulation of cleaved caspase-3 take place in cardiac myocytes in Tg-Sirt1 subjected to I/R ( Figure 5G and 5H) .
We have shown previously that Sirt1 reduces oxidative stress in the heart and cardiac myocytes therein under stress conditions. Because both MnSOD and Trx1 were upregulated in Tg-Sirt1 hearts subjected to I/R, we examined whether oxidative stress was attenuated in Tg-Sirt1 hearts. As expected, staining with anti-8-OHdG antibody, a marker of oxidative DNA damage, was significantly weaker in Tg-Sirt1 than in nontransgenic mice after I/R ( Figure 5I) . Conversely, the level of 8-OHdG staining was significantly enhanced in cardiac-specific Sirt1 Ϫ/Ϫ mice compared with wild-type mice after I/R ( Figure IV in the online-only Data Supplement).
Sirt1-Induced Upregulation of MnSOD Is Partially Mediated by FoxO1
Sirt1 deacetylates FoxO transcription factors, thereby stimulating FoxO-mediated transcription of antioxidants. 12 We therefore examined the role of FoxO in mediating Sirt1-mediated upregulation of MnSOD in cardiac myocytes. Overexpression of Sirt1 increases, whereas knockdown of Sirt1 decreases, total FoxO1 in cultured cardiac myocytes ( Figure 6A and 6B ). Sirt1-induced upregulation of FoxO1 was also observed at the mRNA level ( Figure V in the online-only Data Supplement). On the other hand, overexpression of Sirt1 decreases, whereas knockdown of Sirt1 increases, an acetylated form of FoxO1 ( Figure 6A and 6C). A sample prepared from heart cells treated with p300 acetyltransferase exhibited strong acetylation of FoxO1, thereby serving as a positive control for this experiment. Sirt1-mediated upregulation of MnSOD was significantly attenuated in the presence of FoxO1 knockdown in cultured cardiac myocytes ( Figure 6D and 6E) . These results suggest that FoxO1 plays an essential role in mediating Sirt1-induced upregulation of Mn-SOD. To test whether Sirt1 stimulates FoxO1-mediated transcription, we examined the effect of Sirt1 on the activity of 
3xIRS-luc, a reporter gene containing 3 repeats of the FoxO1
binding site in the insulin-responsive sequence within the insulin-like growth factor-binding protein 1 promoter. 27 Sirt1 significantly increased the activity of 3xIRS-luc, an effect that was abolished in the presence of sirtinol ( Figure 6F ). This result suggests that Sirt1 increases FoxO1-mediated transcription. To test whether Sirt1-induced upregulation of antioxidants reduces oxidative stress, we examined the effect of Sirt1 overexpression on increases in oxidative stress induced by chelerythrine treatment. We have shown previously that chelerythrine increases oxidative stress, thereby inducing apoptosis in cardiac myocytes. Sirt1 significantly attenuated chelerythrine-induced increases in oxidative stress, as evaluated with Dichlorofluorescin diacetate staining. Importantly, inhibition of oxidative stress by Sirt1 was reversed when FoxO1 was downregulated ( Figure VI in the online-only Data Supplement). These results suggest that Sirt1 inhibits oxidative stress in cardiac myocytes through FoxO1dependent mechanisms.
Sirt1 Plays an Important Role in Mediating Nuclear Localization of FoxO1 in the Mouse Heart
To clarify the role of Sirt1 in regulating FoxO1-mediated transcription in the heart in vivo, we examined localization of FoxO1 in the heart with immunostaining. In sham-operated nontransgenic or wild-type hearts, nuclear staining of FoxO1 was not prominent. However, I/R significantly increased nuclear staining of FoxO1 in control hearts. I/R-induced increases in the nuclear staining of FoxO1 were significantly enhanced in Tg-Sirt1 hearts, whereas they were significantly attenuated in cardiac-specific Sirt1 Ϫ/Ϫ hearts (Figure 7) . These results suggest that Sirt1 positively mediates nuclear localization of FoxO1 in the mouse heart in vivo.
Discussion
Our results suggest that Sirt1 plays a protective role against myocardial I/R in the heart in vivo. Together with the cardioprotective actions of Sirt1 against aging and oxidative stress, 22 our results suggest that stimulation of Sirt1 could represent a novel modality to protect the heart from ischemic heart disease.
Our results suggest that the level of Sirt1 is downregulated by I/R. We have shown previously that expression of Sirt1 is upregulated by certain stresses in the heart, including aging, oxidative stress, and heart failure, 21, 22 thereby protecting the heart as a compensatory mechanism. Thus, the regulation of Sirt1 expression appears to be stimulus specific, and the compensatory mechanism of Sirt1 against stress does not operate in response to I/R. Because ischemic preconditioning induced by repetitive brief periods of ischemia prevented I/R-mediated downregulation of Sirt1, it is possible that expression of Sirt1 is also regulated by the extent of ischemia. At present, the molecular mechanism mediating downregulation of Sirt1 during I/R remains to be elucidated.
Both loss-and gain-of-function experiments suggest that Sirt1 plays a protective role against I/R injury in the heart. Because the reversal of Sirt1 downregulation through overexpression of Sirt1 in transgenic mice reduced I/R-induced myocardial injury, downregulation of endogenous Sirt1 during I/R may contribute to myocardial injury. We have shown previously that overexpression of Nampt, an enzyme critically regulating NAD ϩ synthesis in cardiac myocytes, in transgenic mice also reduced I/R-induced myocardial injury. 28 Therefore, interventions to increase either protein expression or activity of Sirt1 during I/R appear to be protective.
Resveratrol protects the heart from I/R injury in experimental animals. 29 Although resveratrol has the ability to stimulate Sirt1, 3 whether stimulation of Sirt1 is mediated directly through interaction between the 2 molecules or secondarily through intermediates remains to be elucidated. 30 Furthermore, the cardioprotective effect of resveratrol could be mediated by Sirt1-independent mechanisms, such as the antioxidant effect of resveratrol. 31 Our results suggest that stimulation of Sirt1 can reduce I/R injury. It would be interesting to compare the molecular mechanisms through which specific stimulation of Sirt1 and resveratrol inhibits I/R injury, with the use of the animal models described here.
Our results suggest that Sirt1 upregulates cardioprotective molecules, including MnSOD, Trx1, and Bcl-xL, and downregulates proapoptotic molecules, including Bax. We have shown previously that Sirt1 deacetylates p53, thereby inhibiting apoptosis of cardiac myocytes in response to serum starvation in vitro. 21 Because Bax is positively regulated by p53, 32 the protective effect of Sirt1 may be mediated in part through deacetylation and suppression of p53. In fact, the level of acetylated p53 is significantly lower in Tg-Sirt1 than in nontransgenic mice. 22 In addition, Sirt1 deacetylates FoxO, thereby stimulating expression of genes mediating cellprotective effects. 12 We show that Sirt1 stimulates transcription through FoxO1 and enhances I/R-induced nuclear localization of FoxO1 in the heart. Furthermore, Sirt1 stimulates expression of MnSOD in cultured cardiac myocytes, and FoxO1 plays an essential role in mediating Sirt1-induced upregulation of MnSOD. Importantly, Sirt1 inhibits oxidative stress in cardiac myocytes through FoxO1-dependent mechanisms ( Figure VI in the online-only Data Supplement). We propose that coordinated regulation of these cell-protective and cell death-promoting molecules mediates the protective effect of Sirt1 under I/R. Consequently, upregulation of Sirt1 significantly attenuates oxidative stress and activation of caspase-3 in the heart during I/R. Many of the molecular changes by either upregulation or downregulation of Sirt1 were observed only in the context of I/R but not at basal conditions. Thus, additional I/R-dependent mechanisms regulating expression of antiapoptotic/proapoptotic molecules and/or nuclear localization of FoxO1 appear to exist. The manner in which Sirt1 protects the heart during I/R in vivo and the role of FoxO1 in mediating the protective effect of Sirt1 require further investigation.
We have shown recently that Nampt, an enzyme stimulating NAD ϩ synthesis, protects the heart from prolonged ischemia. 28 Because Nampt increases the activity of Sirt1, 28 Sirt1 may protect the heart from I/R not only by reducing reperfusion injury but also by protecting the heart from prolonged ischemia. We have found recently that Sirt1 and FoxO coordinately activate autophagy in response to glucose starvation in cardiac myocytes in vitro (N. Hariharan, BS, et al, unpublished data, 2010). Although the molecular mechanism through which Sirt1 protects against myocardial injury caused by prolonged ischemia remains to be elucidated in vivo, Sirt1 might stimulate autophagy, thereby inhibiting myocardial cell death during prolonged ischemia. In any case, Figure 7 . Sirt1 enhances nuclear localization of FoxO1 in response to I/R. Nontransgenic (NTg), Tg-Sirt1, and cardiac-specific Sirt1 Ϫ/Ϫ mice were subjected to I/R or sham operation. Twenty-four hours after reperfusion, the heart was subjected to immunostaining with antitroponin T antibody (red), anti-FoxO1 antibody (green), and DAPI (blue). FoxO1-positive nuclei/ total nuclei were evaluated and expressed as percentage.
stimulation of Sirt1 is an attractive modality to reduce myocardial injury that can be caused by both ischemia and reperfusion in patients suffering from acute myocardial infarction.
Sirt1 is involved in lifespan extension in lower organisms under conditions of calorie restriction. 33 Stimulation of Sirt1 by a small-molecule compound reduces the mortality of obese mice on a high-calorie diet. 34 Although the molecular mechanism mediating the lifespan extension remains to be elucidated in mammals, currently well-accepted hypotheses include the hormesis hypothesis in which accumulation of stress resistance conferred by nonlethal stress leads to lifespan extension. 20 Stimulation of Sirt1 may confer resistance to I/R injury to the heart, which could be a novel mechanism of cardioprotection against cardiac stress. 23 Endogenous mechanisms of lifespan extension are stimulated by low-grade stress, such as calorie restriction. The fact that downregulation of Sirt1 under I/R is attenuated in the presence of preconditioning suggests that stimulation of Sirt1 by a low grade of repetitive stress may partly mediate the beneficial effect of preconditioning.
We have shown previously that the antiaging effect of Sirt1 is dose dependent and that a very high dose of Sirt1 actually induces heart failure. 22 It has also been shown that the cardioprotective effect of resveratrol is dose dependent. 35 Thus, the extent of Sirt1 stimulation should be addressed carefully when stimulation of Sirt1 is considered for treatment of I/R injury in the future.
In summary, Sirt1 has a cardioprotective effect against I/R. Sirt1 upregulates cardioprotective molecules and downregulates proapoptotic molecules during I/R, thereby attenuating oxidative stress and inhibiting apoptosis. Thus, activation of Sirt1 could be a novel method of cardioprotection against cardiac I/R.
